{Reference Type}: Journal Article
{Title}: Highlights from the 2024 ASCO Genitourinary Symposium: focus on urothelial and prostate cancer.
{Author}: Strusi A;Pinterpe G;Ciccarese C;Pedone RR;Sarcina M;Sardaro V;Belletto R;Totaro A;Racioppi M;Berardi R;Tortora G;Iacovelli R;
{Journal}: Expert Rev Anticancer Ther
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jun 27
{Factor}: 3.627
{DOI}: 10.1080/14737140.2024.2370384
{Abstract}: The 2024 ASCO Genitourinary Cancer Symposium, this year celebrating the 20th anniversary, delved into key advancements in urothelial carcinoma (UC) and prostate cancer (PC). For UC, insights emerged from adjuvant pembrolizumab for muscle-invasive urothelial carcinoma, and from the efficacy of the EV-302 study of enfortumab vedotin +pembrolizumab in the metastatic setting. In PC, adjuvant therapy with high-dose radiotherapy schedules plus long-t erm ADT was explored. In metastatic castration-resistant PC, highlights included a novel combo (cabozantinib+atezolizumab) for poor prognosis patients; confirmed benefits of ARSI+PARPi in BRCA-mutated patients; and safety considerations for ARSI treatments. The symposium continued its role as an indispensable platform for shaping specialized oncological care.